The Numbers Got Worse — Fast

This outbreak crossed a grim milestone. According to the Wall Street Journal, the DRC's current Ebola crisis is now the third-largest in recorded history — and it got there in a matter of weeks.

The outbreak is caused by the Bundibugyo strain of Ebola. The strain's significance lies in one critical fact: the two licensed Ebola vaccines that exist — Ervebo, and the two-dose Zabdeno/Mvabea regimen — were developed specifically to fight the Zaire strain of Ebola. Not Bundibugyo.

The Vaccine Gap Nobody Wants to Explain Clearly

Those vaccines worked spectacularly against Zaire. Ervebo hit over 95% efficacy in trials and 84% overall effectiveness, according to Wellcome, the UK health foundation that helped fund its development. It was approved by the FDA in 2019 and helped contain the catastrophic 2018-2020 DRC outbreak — the second largest in history.

Bundibugyo is a different animal. Scientifically related, but different enough that nobody knows how much cross-protection the Zaire vaccine provides.

Dr. Anne Ancia, the WHO representative in the DRC, confirmed to CNN that using the existing Ervebo stockpile has been under consideration — but the honest answer is: they don't know if it would work.

What the WHO's Own Q&A Actually Says

The WHO's updated guidance, dated October 16, 2025, states plainly that Ervebo is "the only vaccine currently available in the global stockpile" and that it is prequalified only for Ebola virus disease caused by Orthoebolavirus zairense — the Zaire strain.

For Bundibugyo specifically, the WHO acknowledges "several candidate vaccines are at different stages of development." That translates to: nothing is ready.

The WHO confirms Bundibugyo virus has caused large human outbreaks before — but vaccine development for it lagged because Zaire killed more people and attracted more funding. Logical, maybe. Cold comfort right now.

Bundibugyo's Track Record

This strain isn't new. According to CNN's reporting, the 2007 outbreak along the DRC-Uganda border produced 131 cases and 42 deaths. A 2012 DRC outbreak had 38 confirmed cases and 13 deaths.

Both were contained. But both were much smaller than what's happening now. The speed of this outbreak's growth — hitting third-largest status in history within weeks — is what's different. And it's happening in a high-trafficked part of the country, per the Wall Street Journal, which accelerates spread.

Ebola can kill between 25% and 90% of those infected, depending on strain and care quality, according to CNN. That's not a typo. That range reflects how brutal the disease is when healthcare infrastructure is weak.

The CEPI Money and What It Actually Buys

Our prior coverage reported CEPI committing $62 million across three groups, including $50 million to Moderna for an investigational Bundibugyo vaccine candidate. The Hill confirmed the $50 million figure for Moderna specifically.

That investment does not buy a vaccine that exists right now.

CNN's reporting is explicit — clinical-grade materials for Bundibugyo-targeted vaccines are still months away from human trials. Moderna's mRNA platform is fast by historical standards. It is NOT fast enough to help anyone currently sick in the DRC.

The investment is the right call. It's also largely irrelevant to the people dying today.

What Mainstream Media Is Getting Wrong

Left-leaning outlets like CNN frame this primarily as a story about vaccine inequality and underfunding — implying that if only more money had been spent earlier, we'd have a vaccine now. That's partially true, but it obscures a harder reality: Bundibugyo is rare enough that even a fully funded global health system would have deprioritized it over Zaire, which killed 11,000 people in West Africa alone.

The more accurate framing is this: the global health apparatus made a rational bet on the most common killer and won. Now a rare strain is surging and they're scrambling. That's not negligence. That's triage.

Center-right outlets are largely treating this as a distant humanitarian story without examining what the US funding posture looks like right now. That gap in coverage deserves scrutiny.

What This Means for Regular People

If you're not in the DRC or traveling there, your personal risk is effectively zero right now. Ebola doesn't spread through the air.

But the broader lesson stands: the world has two licensed Ebola vaccines and zero of them work against the strain currently spreading. The global health apparatus made a rational bet on the most common killer. Now a rare strain is surging. Money was committed. Vaccines are being developed. None of it helps the people in Goma getting their temperatures checked at hospital entrances today.

Facts don't wait for clinical trials.